CU20170168A7 - Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina - Google Patents

Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina

Info

Publication number: CU20170168A7
Authority: CU; Cuba
Prior art keywords: emtricitabina; pharmaceutical formulations; include tenofovir; tenofovir; pharmaceutically acceptable
Prior art date: 2015-06-30

Application number

CUP2017000168A

Other languages

English (en)

Spanish (es)

Inventor

Joanna M Koziara

Scott Mccallister

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-30

Filing date

2016-06-29

Publication date

2018-07-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170168(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-29 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2018-07-05 Publication of CU20170168A7 publication Critical patent/CU20170168A7/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

CUP2017000168A 2015-06-30 2016-06-29 Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina CU20170168A7 (es)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562187113P	2015-06-30	2015-06-30
US201662298373P	2016-02-22	2016-02-22
US201662301429P	2016-02-29	2016-02-29
US201662317286P	2016-04-01	2016-04-01
PCT/US2016/040158 WO2017004244A1 (en)	2015-06-30	2016-06-29	Pharmaceutical formulations comprising tenofovir and emtricitabine

Publications (1)

Publication Number	Publication Date
CU20170168A7 true CU20170168A7 (es)	2018-07-05

Family

ID=56418608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CUP2017000168A CU20170168A7 (es)	2015-06-30	2016-06-29	Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina

Country Status (26)

Country	Link
US (8)	US20170000807A1 (xx)
EP (9)	EP4233846B1 (xx)
JP (3)	JP6667556B2 (xx)
KR (2)	KR102313668B1 (xx)
CN (2)	CN107847450A (xx)
AU (3)	AU2016287500B2 (xx)
BR (1)	BR112017027843A2 (xx)
CA (1)	CA2990210C (xx)
CL (1)	CL2017003320A1 (xx)
CO (1)	CO2017013293A2 (xx)
CU (1)	CU20170168A7 (xx)
DO (1)	DOP2017000306A (xx)
EA (1)	EA201792592A1 (xx)
EC (1)	ECSP17084331A (xx)
ES (5)	ES3007987T3 (xx)
HK (1)	HK1248547A1 (xx)
IL (1)	IL256364A (xx)
MA (1)	MA50541A (xx)
MX (1)	MX2017016806A (xx)
PE (1)	PE20180411A1 (xx)
PH (1)	PH12017502431A1 (xx)
PL (6)	PL4070787T3 (xx)
PT (5)	PT3607939T (xx)
SI (5)	SI4527467T1 (xx)
SV (1)	SV2017005601A (xx)
WO (1)	WO2017004244A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA030003B1 (ru)	2012-12-21	2018-06-29	Джилид Сайэнс, Инк.	Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
WO2016106050A1 (en)	2014-12-26	2016-06-30	Emory University	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP4233846B1 (en)	2015-06-30	2024-12-04	Gilead Sciences, Inc.	Pharmaceutical formulations
CN113546052A (zh)	2015-11-09	2021-10-26	吉利德科学公司	治疗人免疫缺陷病毒的治疗组合物
EP3582773A4 (en)	2017-02-17	2021-03-10	Eidos Therapeutics, Inc.	PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
WO2018153977A1 (en) *	2017-02-24	2018-08-30	Hexal Ag	Stable composition of tenofovir alafenamide
US11191763B2 (en)	2017-03-20	2021-12-07	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	HIV post-exposure prophylaxis
RU2662160C9 (ru) *	2017-07-03	2018-10-22	Александрович Иващенко Андрей	Комбинированный лекарственный препарат для терапии вирусных инфекций
RU2020116571A (ru)	2017-12-07	2021-11-22	Эмори Юниверсити	N4-гидроксицитидин и производные и связанные с этим противовирусные применения
WO2019183463A1 (en)	2018-03-23	2019-09-26	Eidos Therapeutics, Inc.	Methods of treating ttr amyloidosis using ag10
LT3836920T (lt)	2018-08-17	2026-01-26	Eidos Therapeutics, Inc.	Ag10 farmacinės formos
CN111096954B (zh) *	2018-10-29	2022-09-16	江苏豪森药业集团有限公司	一种用于抗病毒感染的药物组合物及制备方法
MA56449A (fr) *	2019-07-03	2022-05-11	Janssen Sciences Ireland Unlimited Co	Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
CN110251476B (zh) *	2019-08-01	2022-08-09	海思科制药(眉山)有限公司	一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) *	2019-12-31	2020-03-27	常州恒邦药业有限公司	一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) *	2020-02-19	2021-05-21	台灣森本生物科技開發股份有限公司	含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN117653644A (zh) *	2022-08-24	2024-03-08	安徽贝克制药股份有限公司	包含恩曲他滨、替诺福韦和利匹韦林的药物组合物
CN117653634A (zh) *	2022-08-24	2024-03-08	安徽贝克制药股份有限公司	包含恩曲他滨、替诺福韦和比克替拉韦的药物组合物
WO2024211882A1 (en) *	2023-04-07	2024-10-10	Navinta, Llc	Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN117338733B (zh) *	2023-10-12	2024-05-28	杭州和泽坤元药业有限公司	一种富马酸替诺福韦二吡呋酯片及其制备工艺
WO2025229473A1 (en) *	2024-05-01	2025-11-06	Lupin Limited	Tenofovir alafenamide compositions
CN119174735A (zh) *	2024-09-03	2024-12-24	安徽贝克生物制药有限公司	一种含利匹韦林的复方片及制备方法
CN119139247A (zh) *	2024-09-05	2024-12-17	安徽贝克生物制药有限公司	一种恩曲他滨丙酚替诺福韦复方片及制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6642245B1 (en)	1990-02-01	2003-11-04	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
HRP20030047B1 (hr)	2000-07-21	2016-02-26	Gilead Sciences, Inc.	Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
WO2004024078A2 (en)	2002-09-11	2004-03-25	Merck & Co., Inc.	Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
US7176220B2 (en)	2002-11-20	2007-02-13	Japan Tobacco Inc.	4-oxoquinoline compound and use thereof as pharmaceutical agent
PT1583542E (pt)	2003-01-14	2008-09-17	Gilead Sciences Inc	Composições e métodos para terapia de combinação antiviral
MY134672A (en)	2004-05-20	2007-12-31	Japan Tobacco Inc	Stable crystal of 4-oxoquinoline compound
US8633219B2 (en)	2004-05-21	2014-01-21	Japan Tobacco Inc.	Combination therapy
JP4953297B2 (ja)	2004-09-15	2012-06-13	塩野義製薬株式会社	Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
DK3187225T3 (da)	2005-04-28	2022-02-28	Viiv Healthcare Co	Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20070219243A1 (en)	2005-12-30	2007-09-20	Kearney Brian P	Method for improving the pharmacokinetics of HIV integrase inhibitors
US9044509B2 (en)	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
PT3150586T (pt)	2007-02-23	2020-03-31	Gilead Sciences Inc	Moduladores de propriedades farmacocinéticas de agentes terapêuticos
WO2009006203A1 (en)	2007-06-29	2009-01-08	Gilead Sciences, Inc.	Therapeutic compositions and the use thereof
EA201591353A1 (ru)	2008-05-02	2016-01-29	Джилид Сайэнс, Инк.	Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PL2393485T3 (pl)	2009-02-06	2015-12-31	Gilead Sciences Inc	Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
DK2480552T3 (en)	2009-09-21	2017-02-20	Gilead Sciences Inc	2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
NZ610729A (en)	2010-11-19	2015-10-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
AP3639A (en)	2011-08-16	2016-03-13	Gilead Sciences Inc	Tenofovir alafenamide hemifumarate
WO2013116730A1 (en) *	2012-02-03	2013-08-08	Gilead Sciences, Inc.	Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
US20140221355A1 (en)	2012-12-21	2014-08-07	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA030003B1 (ru)	2012-12-21	2018-06-29	Джилид Сайэнс, Инк.	Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
US9287278B2 (en)	2013-03-01	2016-03-15	Microsemi SoC Corporation	Non-volatile push-pull non-volatile memory cell having reduced operation disturb and process for manufacturing same
US20140296266A1 (en)	2013-03-01	2014-10-02	Gilead Sciences, Inc.	Therapeutic compounds
WO2014184553A1 (en)	2013-05-15	2014-11-20	Cipla Limited	Pharmaceutical antiretroviral compositions
EA201690146A1 (ru) *	2013-08-14	2016-07-29	Ратиофарм Гмбх	Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
EA201690473A1 (ru)	2013-08-27	2017-03-31	ГАЙЛИД ФАРМАССЕТ ЭлЭлСи	Комбинированный состав двух противовирусных соединений
CZ2013985A3 (cs) *	2013-12-09	2015-06-17	Zentiva, K.S.	Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (xx)	2014-06-20	2018-06-23
EP4233846B1 (en)	2015-06-30	2024-12-04	Gilead Sciences, Inc.	Pharmaceutical formulations
CA2921336A1 (en)	2015-06-30	2016-12-30	Gilead Sciences, Inc.	Pharmaceutical formulations

2016
- 2016-06-29 EP EP23162978.3A patent/EP4233846B1/en active Active
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active Active
- 2016-06-29 ES ES23162978T patent/ES3007987T3/es active Active
- 2016-06-29 SI SI201631957T patent/SI4527467T1/sl unknown
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 CA CA2990210A patent/CA2990210C/en active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/xx unknown
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 EP EP26175955.9A patent/EP4759366A3/en active Pending
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 HK HK18108248.3A patent/HK1248547A1/zh unknown
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/en active Active
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 EP EP26164598.0A patent/EP4751776A3/en active Pending
- 2016-06-29 EP EP24216441.6A patent/EP4527467B1/en active Active
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/en not_active Ceased
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/en active Active
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active Active
- 2016-06-29 PL PL23162978.3T patent/PL4233846T3/pl unknown
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 PT PT242164416T patent/PT4527467T/pt unknown
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/en active Active
- 2016-06-29 EP EP26173766.2A patent/EP4755454A3/en active Pending
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/en active Active
- 2016-06-29 PL PL24216441.6T patent/PL4527467T3/pl unknown
- 2016-06-29 CN CN202411894523.5A patent/CN119606990A/zh active Pending
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending
2025
- 2025-02-07 US US19/048,549 patent/US20250281412A1/en active Pending
2026
- 2026-01-16 US US19/451,093 patent/US12629338B1/en active Active
- 2026-01-16 US US19/451,185 patent/US20260137623A1/en active Pending
- 2026-01-27 US US19/461,014 patent/US12661323B2/en active Active
- 2026-01-30 US US19/464,945 patent/US12648911B2/en active Active
- 2026-02-20 US US19/545,594 patent/US12678408B2/en active Active

Also Published As

Publication number	Publication date
US20260151344A1 (en)	2026-06-04
EP4070788B1 (en)	2023-03-22
US20260137623A1 (en)	2026-05-21
AU2021202009A1 (en)	2021-04-29
AU2019210558B2 (en)	2021-04-22
KR20200067937A (ko)	2020-06-12
US20180177734A1 (en)	2018-06-28
CN107847450A (zh)	2018-03-27
AU2019210558A1 (en)	2019-08-15
ES2945896T3 (es)	2023-07-10
US12629338B1 (en)	2026-05-19
PH12017502431A1 (en)	2018-07-02
ES3007987T3 (en)	2025-03-21
EP4759366A2 (en)	2026-06-17
EP4751776A3 (en)	2026-07-29
ECSP17084331A (es)	2018-01-31
JP2021185188A (ja)	2021-12-09
WO2017004244A1 (en)	2017-01-05
EA201792592A1 (ru)	2018-06-29
CA2990210C (en)	2021-01-12
US12678408B2 (en)	2026-07-14
EP4755454A3 (en)	2026-08-05
EP4070787A1 (en)	2022-10-12
PL4070787T3 (pl)	2023-07-24
SI3316868T1 (sl)	2020-04-30
US20260183244A1 (en)	2026-07-02
EP4527467A3 (en)	2025-05-21
AU2016287500A1 (en)	2018-01-18
SI4070788T1 (sl)	2023-06-30
PL4233846T3 (pl)	2025-03-24
US20260137622A1 (en)	2026-05-21
EP4233846B1 (en)	2024-12-04
BR112017027843A2 (pt)	2018-09-04
KR102313668B1 (ko)	2021-10-19
AU2016287500B2 (en)	2019-05-02
EP4070787B1 (en)	2023-03-01
US12648911B2 (en)	2026-06-09
MX2017016806A (es)	2018-05-07
EP4759366A3 (en)	2026-08-12
JP6667556B2 (ja)	2020-03-18
US12661323B2 (en)	2026-06-23
PT4070788T (pt)	2023-06-06
US20170000807A1 (en)	2017-01-05
EP4755454A2 (en)	2026-06-10
AU2021202009B2 (en)	2023-04-13
EP4527467A2 (en)	2025-03-26
PT3316868T (pt)	2020-04-21
MA50541A (fr)	2021-04-07
SI3607939T1 (sl)	2022-10-28
IL256364A (en)	2018-02-28
EP3316868B1 (en)	2020-02-19
PL4070788T3 (pl)	2023-07-10
US20260151343A1 (en)	2026-06-04
EP4233846C0 (en)	2024-12-04
ES2786549T3 (es)	2020-10-13
PT4527467T (pt)	2026-06-01
US20250281412A1 (en)	2025-09-11
PL3607939T3 (pl)	2022-11-07
CN119606990A (zh)	2025-03-14
SV2017005601A (es)	2018-05-04
SI4527467T1 (sl)	2026-07-31
SI4070787T1 (sl)	2023-07-31
ES2945345T3 (es)	2023-06-30
ES2925246T3 (es)	2022-10-14
EP4233846A2 (en)	2023-08-30
PL3316868T3 (pl)	2020-10-19
EP3607939B1 (en)	2022-06-01
KR20180021134A (ko)	2018-02-28
HK1248547A1 (zh)	2018-10-19
CL2017003320A1 (es)	2018-07-13
PE20180411A1 (es)	2018-03-01
CA2990210A1 (en)	2017-01-05
EP3316868A1 (en)	2018-05-09
JP2020079304A (ja)	2020-05-28
EP3607939A1 (en)	2020-02-12
EP4070788A1 (en)	2022-10-12
PT3607939T (pt)	2022-09-12
DOP2017000306A (es)	2018-01-15
JP6978534B2 (ja)	2021-12-08
CO2017013293A2 (es)	2018-05-31
EP4233846A3 (en)	2023-10-04
JP2018519297A (ja)	2018-07-19
KR102121329B1 (ko)	2020-06-17
EP4751776A2 (en)	2026-06-03
EP4527467B1 (en)	2026-03-18
PT4070787T (pt)	2023-05-22
PL4527467T3 (pl)	2026-07-06

Publication	Publication Date	Title
DOP2017000306A (es)	2018-01-15	Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
EP4045480A4 (en)	2023-11-22	PHARMACEUTICAL FORMULATIONS
IL264210A (en)	2019-02-28	High-strength oral cannabinoid dosage forms
MX2017016802A (es)	2018-09-06	Formulaciones farmaceuticas.
IL264065A (en)	2019-01-31	Oral gastroretentive formulations and uses thes thereof
MA46867A (fr)	2019-09-25	Formulations pharmaceutiques
HUP1700253A1 (hu)	2019-01-28	Szilárd orális gyógyszerkészítmények
PH12016501841A1 (en)	2017-01-09	Immunosuppressant formulation
MA55015A (fr)	2021-12-29	Formulations pharmaceutiques
ZA202006570B (en)	2021-09-29	Pharmaceutical formulations
MX2018005358A (es)	2018-06-06	Comprimido de dosis alta que contiene mesalazina optimizado.
GB2591396B (en)	2023-06-07	Pharmaceutical suspension for oral dosage
EP3746080A4 (en)	2021-11-17	PHARMACEUTICAL FORMULATIONS
EA201991286A1 (ru)	2019-10-31	Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX385513B (es)	2025-03-18	Composiciones farmaceuticas que comprenden safinamida.
EP3697393A4 (en)	2021-10-13	DOSAGE FORMS
EP3651800C0 (en)	2024-04-10	HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS
ZA201804275B (en)	2023-04-26	Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
EA201991007A1 (ru)	2019-08-30	Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
EP3512507A4 (en)	2019-11-13	ORAL MEDICINAL FORMULATIONS
CR20170601A (es)	2018-02-28	Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
HUE062682T2 (hu)	2023-11-28	Ibuprofén tartalmú orális gyógyszerészeti készítmény
HUE056233T2 (hu)	2022-02-28	Ibuprofén készítmények közvetlen orális beadásra
JOP20170198A1 (ar)	2019-06-30	صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
EP3955907A4 (en)	2022-12-28	PHARMACEUTICAL FORMULATIONS CONTAINING P2Y14 ANTAGONISTS